Provectus Biopharmaceuticals, Inc.

Release Summary

Provectus Biopharmaceuticals Completes Patient Accrual for PH-10 Phase 2 Clinical Study of Cellular and Immunologic Changes in the Skin

Provectus Biopharmaceuticals, Inc.